Literature DB >> 34374819

Long-term vascular access for infants with moderate to severe osteogenesis imperfecta.

Courtney L Devin1, Emily Sagalow1, Annalise Penikis1, Cristina M McGreal2, Michael B Bober2, Loren Berman3,4.   

Abstract

PURPOSE: Osteogenesis imperfecta (OI) is a genetic disorder that causes skeletal fragility. For the most fragile infants and young children with OI, intravenous (IV) bisphosphonate administration is essential, but IV access attempts often cause fractures. Port-a-caths help prevent these events, but some surgeons are hesitant to insert these devices in these infants due to lack of data on their safety.
METHODS: Retrospective study of pediatric patients with OI who underwent port-a-cath placement from 1999 to 2018; incidence of complications such as infection and thrombosis and need for reoperation or replacement are described.
RESULTS: Port-a-caths were placed in 17 patients with OI (median age, 8 mos [5-23 mos]; median weight, 5.8 kg [3.96-9.08 kg]) and remained in place for a median of 53.5 mos (10-127 mos). One port-a-cath was replaced because of thrombosis. Two port-a-caths were removed because of malfunction, one for skin erosion, and one for infection. In these five cases, replacement was not needed because patients could safely tolerate IV access. Two patients have their port-a-cath in place and the remaining ten patients had theirs removed electively as it was no longer needed.
CONCLUSION: Port-a-cath placement in pediatric patients with OI is safe and efficacious for durable central access, enabling reliable IV bisphosphonate delivery and reducing iatrogenic trauma.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Bisphosphonates; Osteogenesis imperfect; Port-a-cath; Surgery; Venous access

Year:  2021        PMID: 34374819     DOI: 10.1007/s00383-021-04975-2

Source DB:  PubMed          Journal:  Pediatr Surg Int        ISSN: 0179-0358            Impact factor:   1.827


  13 in total

Review 1.  Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment.

Authors:  P Trejo; F Rauch
Journal:  Osteoporos Int       Date:  2016-08-05       Impact factor: 4.507

2.  Early bisphosphonate treatment in infants with severe osteogenesis imperfecta.

Authors:  Franco Antoniazzi; Giorgio Zamboni; Silvana Lauriola; Luisa Donadi; Silvano Adami; Luciano Tatò
Journal:  J Pediatr       Date:  2006-08       Impact factor: 4.406

3.  Characterising and treating osteogenesis imperfecta.

Authors:  Nick Bishop
Journal:  Early Hum Dev       Date:  2010-09-16       Impact factor: 2.079

4.  Identifying and reducing early complications of surgical central lines in infants and toddlers.

Authors:  Sara C Fallon; Michael E Kim; Caraciolo J Fernandes; Sanjeev A Vasudevan; Jed G Nuchtern; Eugene S Kim
Journal:  J Surg Res       Date:  2014-04-13       Impact factor: 2.192

5.  Genetic heterogeneity in osteogenesis imperfecta.

Authors:  D O Sillence; A Senn; D M Danks
Journal:  J Med Genet       Date:  1979-04       Impact factor: 6.318

Review 6.  Percutaneous central access in patients younger than 5 years: size does matter.

Authors:  James E Janik; Sarah J Conlon; Joseph S Janik
Journal:  J Pediatr Surg       Date:  2004-08       Impact factor: 2.545

Review 7.  Osteogenesis imperfecta.

Authors:  Antonella Forlino; Joan C Marini
Journal:  Lancet       Date:  2015-11-03       Impact factor: 79.321

8.  Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.

Authors:  F H Glorieux; N J Bishop; H Plotkin; G Chabot; G Lanoue; R Travers
Journal:  N Engl J Med       Date:  1998-10-01       Impact factor: 91.245

9.  Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.

Authors:  L A DiMeglio; L Ford; C McClintock; M Peacock
Journal:  Bone       Date:  2004-11       Impact factor: 4.398

Review 10.  Managing the patient with osteogenesis imperfecta: a multidisciplinary approach.

Authors:  Caroline Marr; Alison Seasman; Nick Bishop
Journal:  J Multidiscip Healthc       Date:  2017-04-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.